<DOC>
	<DOC>NCT02034058</DOC>
	<brief_summary>The primary objective of this study is to evaluate the rate of stroke and/or death in patients treated with the Wingspan Stent System, according to the Indications for Use, within 72 hours post procedure.</brief_summary>
	<brief_title>Post Market Surveillance Study of the Wingspan Stent System</brief_title>
	<detailed_description>This research study is a Food and Drug Administration (FDA) mandated post market surveillance study of the Wingspan® Stent System, also known as the WEAVE™ Trial. The purpose of this trial is to fulfill a FDA requirement to evaluate the rate of stroke and/or death within 72 hours of the procedure, in patients who have a Wingspan Stent implanted in accordance with the Indications for Use.</detailed_description>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Intracranial Arteriosclerosis</mesh_term>
	<criteria>All patients for whom treatment with the Wingspan Stent System is considered.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Wingspan Stent System</keyword>
	<keyword>Wingspan Stent</keyword>
	<keyword>Intracranial Stent</keyword>
	<keyword>Ischemic Stroke</keyword>
	<keyword>Intracranial Atherosclerotic Disease</keyword>
	<keyword>Intracranial Stenosis</keyword>
</DOC>